Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) EBIT Margin (2021 - 2025)

Historic EBIT Margin for Krystal Biotech (KRYS) over the last 4 years, with Q3 2025 value amounting to 42.3%.

  • Krystal Biotech's EBIT Margin rose 155000.0% to 42.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.39%, marking a year-over-year increase of 310100.0%. This contributed to the annual value of 22.61% for FY2024, which is 2390400.0% up from last year.
  • As of Q3 2025, Krystal Biotech's EBIT Margin stood at 42.3%, which was up 155000.0% from 40.93% recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's EBIT Margin registered a high of 962.0% during Q1 2021, and its lowest value of 303.8% during Q3 2023.
  • Over the past 4 years, Krystal Biotech's median EBIT Margin value was 33.87% (recorded in 2025), while the average stood at 85.95%.
  • Per our database at Business Quant, Krystal Biotech's EBIT Margin soared by 3306000bps in 2024 and then surged by 155000bps in 2025.
  • Krystal Biotech's EBIT Margin (Quarter) stood at 962.0% in 2021, then tumbled by -99bps to 7.45% in 2023, then surged by 509bps to 45.35% in 2024, then decreased by -7bps to 42.3% in 2025.
  • Its EBIT Margin was 42.3% in Q3 2025, compared to 40.93% in Q2 2025 and 41.02% in Q1 2025.